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Introduction.	
The	ISTH	SSC	on	Factor	VIII/IX	has	previously	issued	guidelines	for	studies	assessing	the	
pharmacokinetics	(PK)	of	factor	concentrates	[1,2].	They	suggested	drawing	10	or	11	blood	samples	
over	a	period	of	32-48h	or	50-72h,	after	infusing	25-50	or	50-75	IU/kg,	respectively	for	factor	VIII	(FVIII)	
or	factor	IX	(FIX),	in	cohorts	of	12-15	patients	with	a	crossover	design.	Such	PK	studies	are	not	ideal	for	
tailoring	the	treatment	of	individual	patients,	mostly	for	the	requirement	of	several	blood	samples.	
Due	to	broad	inter-individual	variation,	the	individual	disposition	of	FVIII	and	FIX	cannot	be	predicted	
from	morphometric	characteristics	and	average	PK	parameters,	but	requires	empirical	assessment	in	
each	individual	[3–6].	Previous	guidance	of	this	ISTH	SSC	described	the	PK	methodology	for	the	
prediction	of	individual	trough	levels	of	FVIII	[7].	The	present	communication,	building	on	recent	
advancements	in	the	population	PK	(PopPK)	of	FVIII	and	FIX	[8],	adds	to	the	former	documents.		
PopPK	models	have	been	derived	for	FVIII	[9–11]	and	FIX	[8,12–14],	enabling	Bayesian	estimation	of	
individual	PK	from	limited	samples	[15,5,6].	PopPK	solutions	are	available	to	support	individual	
forecasting	for	several	factor	concentrates	[16–18].	Observing	the	correlation	between	plasma	factor	
levels	and	bleeding	history	[3,19]	has	prompted	a	graded	approach	to	prophylaxis,	where	appropriate	
target	levels	are	identified	for	different	patients,	considering	the	variability	in	clinical	and	lifestyle	
characteristics	[20–22].	Extended	half-life	(EHL)	concentrates,	whereas	supporting	more	acceptable	
and	less	burdensome	treatment	regimens,	increase	the	complexity	of	dosing	optimization.	A	“trial-
and-error”	approach	to	identify	the	most	appropriate	regimen	for	each	patient	is	less	efficient	for	
achieving	and	maintaining	target	factor	levels	optimized	for	individual	patients.	
The	aim	of	this	document	is	to	provide	guidance	for	performing,	interpreting,	and	applying	individual	
PopPK	assessments	in	routine	clinical	practice.	
	
Practical	recommendation	for	a	limited	sampling	approach	to	individual	PK	profiling.	
1. Adopt	testing	conditions	as	close	as	possible	to	routine	use	of	the	factor	concentrate.	
1.1. Use	any	sample	drawn	during	a	routine	clinical	assessment,	including	samples	drawn	following	
home	infusions.	
1.2. Use	the	first	or	any	subsequent	infusion	of	the	concentrate.	
1.3. Combine	time	points	from	multiple	infusions,	decreasing	the	burden	of	PK	studies.	A	typical	
case	is	using	two	consecutive	infusions	where	the	trough	of	the	first	is	used	also	as	pre-dose	for	
the	second.	
1.4. Do	not	perform	a	wash-out	(box)	for	patients	on	a	regular	treatment	schedule	and	for	whom	
the	baseline	factor	level	(box)	is	known.	Performing	a	wash	out	introduces	ethical	and	practical	
barriers	to	assess	individual	PK	in	routine	clinical	care,	and	may	bias	the	assessment	not	
reflecting	the	accumulation	of	clotting	factor	concentrate	which	may	occur	on	standard	
prophylaxis	[7,6].	
1.5. Take	measurements	after	the	dose	the	patient	is	routinely	treated	with.	Individual	PK	
assessment	does	not	require	a	standardized	dose,	and	is	likely	more	informative	when	done	
with	the	dose	the	patient	is	currently	using.	
1.6. Give	preference	to	sampling	in	“non-bleeding”	conditions	if	assessing	PK	for	tailoring	
prophylaxis.	Dedicated	PK	models	have	been	proposed	for	PK	tailoring	of	peri-surgical	
treatment	[23].		
1.7. Repeat	the	PK	assessment	if	a	change	in	PK	over	time	is	anticipated,	as	in	children	[11]	or	in	
patients	with	current	or	past	inhibitors.	
2. Select	the	most	informative	time	points	and	record	the	sampling	time	precisely.	
2.1. For	standard	FVIII	adopt	a	2-3	samples	protocol,	with	samples	at	least	12h	apart	in	the	4-48h	
period	(e.g.	around	4-8,	16-28,	40-60);	the	single	sample	providing	most	information	is	24h	[7].		
2.2. For	standard	FIX	consider	using	a	2	samples	protocol;	24-36h	and	48-60h,	at	least	24h	apart	[8].	
2.3. For	EHL	FVIII	and	FIX	there	have	been	fewer	investigations	performed;	suggestions	below	are	
empirically	derived	and	could	change	over	time:	
2.3.1. For	EHL	FVIII,	add	a	sample	at	60-84h	to	those	indicated	in	2.1.	
2.3.2. For	EHL	FIX,	add	a	sample	at	5-14	days	to	those	indicated	in	2.2.	
2.4. Consider	using	different	time	points	if	patient’s	and	clinic	schedules’	constraints	need	to	be	
accommodated,	but	beware	that	the	impact	of	using	different	points	is	not	yet	well	known.	
2.5. Peak	measurement	is	not	required	for	PopPK	forecasting.	Peak	is	needed	to	calculate	recovery	
(box)	and	might	be	useful	for	other	clinical	purposes.	
2.6. Record	the	start	time	of	the	infusion	and	the	sampling	times	as	precisely	as	possible	using	
calendar	time	(month,	day,	hours,	minutes).	
2.7. Include	a	pre-infusion	sample	when	the	patient	is	infused	in	the	clinic.	
2.8. Obtain	from	the	patient	and	report	the	times	and	doses	of	the	last	three	infusions.	
2.9. Record	covariates,	like	height	(to	calculate	lean	body	weight,	box);	blood	group,	hematocrit,	
and	von	Willebrand	factor	antigen	levels	(which	may	influence	the	PK	of	some	factor	VIII	
concentrates)	[24,25].	
3. Perform	and	record	laboratory	measurements	precisely.	
3.1. Use	an	appropriate	laboratory	test.	For	standard	FVIII	and	FIX	concentrates,	most	clotting	
assays	provide	reliable	results	[26,27].	For	EHL	consider	adopting	appropriate	tests	for	both	
routine	measurements	and	individual	PK	[28].	Record	the	test	(clotting	or	chromogenic,	
activator	and	standard).	
3.2. Report	measurement	as	International	Units	per	milliliter	(IU/mL).	Alternative	units	of	measure	
(e.g.	IU/dL,	or	percent	activity)	can	be	converted	to	a	common	nomenclature.	
3.3. Report	activity	levels	Below	Limit	of	Quantitation	(BLQ,	Box).	If	any	of	the	samples	have	less	
than	detectable	factor	activity	(e.g.	is	reported	as	<	0.01	IU/mL	or	as	value	below	the	limit	of	
quantification),	do	not	discard	the	information,	but	record	it	as	any	other	measurement.	
Ignoring	data	BLQ	may	bias	the	individual	estimate	[29,30].	
4. Adopt	an	optimal	Bayesian	estimation	technique	for	the	individual	PK	profiling.	
4.1. Adopt	a	validated	modelling	process.	We	recommend	against	performing	in	house	PopPK	
estimation,	unless	specific	expertise	is	available.	Performing	Bayesian	estimation	on	limited	
sample	requires	i)	a	population	PK	model,	derived	and	validated	in	a	suitable	population	and/or	
published	in	the	literature,	and	ii)	a	dedicated	statistical	software	(e.g.	Icon	NONMEM,	Phoenix	
NLME,	MRC	WinBUGS).	
4.2. Adopt	a	robust	PopPK	solution.	Dedicated	solutions	for	individual	PK	profiling	on	limited	data	
are	available	(e.g.	WAPPS-Hemo,	www.wapps-hemo.org;	my	PKFit,	www1.mypkfit.com)	[16–
18].	In	making	your	choice	consider	the	characteristics	of	the	solution;	i)	output:	individual	
PopPK	profile,	treatment	regimen	suggestion,	simulation	capabilities;	ii)	technical:	
documentation;	measure	of	certainty	of	the	prediction,	handling	of	BLQ,	active	monitoring	of	
estimates;	iii)	coverage:	estimation	for	one	or	more	specific	concentrates,	generic	molecules;	
iv)	flexibility:	merging	of	multiple	infusion;	integration	in	Electronic	Medical	Record	software;	v)	
business	model/sponsorship:	for	profit,	not	for	profit,	research	orientation.	
4.3. Seek	training	opportunities	to	improve	the	quality	of	individual	PK	assessment.	
4.3.1. We	suggest	performing	or	facilitating	basic	PK	training	of	the	clinical	and	laboratory	staff;	
this	document	is	recommended	as	core	content	for	training	of	those	involved	in	
performing	individual	PK	studies.	
4.3.2. 	We	suggest	educating	persons	with	hemophilia	and	their	caregivers	to	understand	the	
implication	of	individual	PK	profiling	in	choosing	their	treatment	regimen,	the	importance	
of	matching	their	desired	factor	activity	level	with	their	schedule	for	physical	activity,	as	
well	as	how	to	interpret	and	react	to	intercurrent	bleeding	episodes.	
5. Adopt	a	clinical	perspective	in	the	interpretation	and	use	of	the	predicted	PK	profile	
5.1. Use	clinically	meaningful	PK	parameters	for	clinical	decision	making.	
5.1.1. We	recommend	considering	“activity	over	time”	estimates	as	the	most	intuitive	
information	for	building	treatment	regimens	and	for	communication	to	patients.	Time	to	a	
desired	target	activity	level	or	activity	level	at	a	given	time	after	the	infusion	is	the	most	
clinically	relevant	component	of	the	individual	PK	profile,	allowing	health	care	
professionals	and	PWH	or	caregivers	to	target	any	desired	plasma	activity	level	or	to	
decide	about	appropriateness	of	timing	of	infusions	for	different	levels	of	physical	activity.	
5.1.2. Individual	area	under	the	curve,	volume	of	distribution,	terminal	half-life,	clearance,	mean	
residence	time	in	the	blood	or	in	the	body	(box)	may	also	be	estimated.	
5.1.3. 	Choose	the	appropriate	target	activity	level	for	each	individual	patient.	The	advantage	of	
individualized	treatment	based	on	PK	is	not	limited	to	targeting	the	same	trough	(e.g.	0.01	
IU/mL)	for	every	patient	[23].	
5.2. Apply	clinical	judgement	to	assess	the	predicted	PK	profile.	The	Bayesian	estimation	of	
individual	PK	is	a	modeling	process,	combining	information	from	limited	samples	with	that	from	
the	underlying	population.	As	for	any	modelling,	the	result	is	an	approximation.	When	the	
certainty	of	the	prediction	is	reported	and	is	low,	we	recommend	adopting	conservative	
estimates	(if	available)	or	aiming	for	a	target	activity	level	slightly	higher	than	one	would.	
5.3. Prospectively	validate	the	accuracy	of	the	prediction.	The	easiest	and	most	reliable	validation	of	
Bayesian	individual	estimates	is	obtained	by	drawing	new	samples	to	verify	the	predicted	
activity(ies)	at	specific	time	point(s),	e.g.	before	a	dose	(trough	level)	or	at	the	time	point	for	a	
critical	activity	level.	These	samples	can	also	be	used	to	refine	the	PK	profile.	
	
We	believe	that	this	guidance	will	facilitate	better	uptake	of	PopPK	based	tailoring	of	hemophilia	
treatment.	Shared	software	solutions	would	also	support	generation	of	new	data,	further	research,	and	
eventually	updates	of	this	recommendation.	
Acknowledgements:	The	authors	would	like	to	thank	the	additional	members	of	the	ISTH	SSC	working	
group	who	generously	contributed	input	during	the	development	of	this	manuscript:	D.	Lillicrap,	
Queen’s	University,	Kingston,	Canada,	D.	Hart,	Royal	London	Hemophilia	Center,	London,	UK,	M.	
Makris,	Royal	Hallamshire	Hospital,	Sheffield,	UK,	A.	Edginton,	University	of	Kitchener-Waterloo,	
Canada,	S.	Ito,	Hospital	for	Sick	Children,	Toronto,	Canada.	The	authors,	who	retain	the	sole	
responsibility	for	the	final	content	of	the	recommendation,	would	also	like	to	thank	the	following	
colleagues,	who	kindly	agreed	to	review	a	draft	of	this	manuscript	providing	comments	and	suggestions:	
H.	Agers ø,	Novo	Nordisk	A/S,	Denmark;	B.	Beaufils,	LFB,	France;	E.	Berntorp,	Malmö,	Sweden;	A.	
Boban,	Zagreb,	Croatia;	M.	Cnossen,	Erasmus	University	Medical	Center,	Rotterdam,	Netherlands;	S.E.	
Croteau,	Boston	Children’s	Hospital,	Boston,	USA;	J.	Feddern,	Octapharma,	Germany;	M.	Germer,	
Biotest,	Germany;	S.	Jönsson,	Uppsala	University,	Sweden;	J.	Korth-Bradley,	Pfizer,	US;	S.	Lethagen,	
Sobi,	Sweden;	R.	Mathot,	Academic	Medical	Center	,	Amsterdam,	Netherlands;	M.	Morfini,	Florence,	
Italy;	M.	Ragni,	Pittsburgh,	USA;	J.	Roberts,	CSL	Behring,	US;	A.	Shah,	Bayer,	US;	J.	Spears,	Grifols,	USA;	
and	G.	Spotts,	Shire,	Ireland. 
 
Disclosures:	
V	Blanchette	has	received	honoraria	for	participating	in	Educational	events	and	Advisory	Boards	funded	
by	Bayer,	Biogen,	Novartis,	Novo	Nordisk,	Pfizer	and	Shire.	He	is	a	member	of	Data	Safety	Monitoring	
Boards	for	Octapharma	and	Shire.	He	is	Chair	of	the	International	Prophylaxis	Study	Group,	a	
collaborative	study	group	that	receives	funding	support	from	Bayer,	Biogen,	CSL	Behring,	Novo	Nordisk,	
Pfizer	and	Shire.	
J	Blatny	has	received	speaker’s	fees	from	Bayer,	Baxter,	CSL	Behring,	Octapharma,	Pfizer,	Novo	Nordisk;	
performed	consultancy	for	Shire,	Baxter,	Novo	Nordisk	and	Pfizer.	
P	Collins	has	received	research	support	from	CSL	Behring,	Consultancy	fees	from	Novo	Nordisk,	Sobi,	
Shire,	CSL	Behring.	Sponsorship	for	meetings	from	Novo	Nordisk,	CSL	Behring,	Shire.	
K.	Fischer	has	received	speaker’s	fees	from	Bayer,	Baxter,	Biotest,	CSL	Behring,	Biotest	Octapharma,	
Pfizer,	Novo	Nordisk;	performed	consultancy	for	Bayer,	Baxter,	Biogen,	Freeline,	Novo	Nordisk	and	
Pfizer;	and	has	received	research	support	from	Bayer,	Wyeth/Pfizer,	Baxter,	and	Novo	Nordisk.	
A.	Iorio’s	Institution	has	received	project	based	funding	via	research	or	service	agreements	with	Bayer,	
Baxalta/Shire,	Biogen	Idec,	Grifols,	Novo	Nordisk,	Pfizer	and	Octapharma.	
E	Neufeld	has	served	as	a	consultant	for	Novo	Nordisk,	Genentech,	Pfizer,	CSL	Behring,	Kedrion,	
Genentech	and	Octapharma.	He	is	also	a	DSMB	member	for	Bayer.	His	institution	has	received	research	
funds	from	Octapharma.	
All	authors	are	co-investigators	in	the	Web	Accessible	Population	Pharmacokinetic	Service	(WAPPS)	
research	project.	 	
	References	
1		 Lee	M,	Morfini	M,	Schulman	S,	Ingerslev	J.	The	Design	and	Analysis	of	Pharmacokinetic	Studies	of	
Coagulation	Factors.	ISTH	Website,	Scientific	and	Standardization	Committee	Communication.	
2001.	p.	1–9.		
2		 Morfini	M,	Lee	M,	Messori	A.	The	design	and	analysis	of	half-life	and	recovery	studies	for	factor	
VIII	and	factor	IX.	Factor	VIII/Factor	IX	Scientific	and	Standardization	Committee	of	the	
International	Society	for	Thrombosis	and	Haemostasis.	Thromb	Haemost	1991;	66:	384–6.		
3		 Collins	PW,	Fischer	K,	Morfini	M,	Blanchette	VS,	Bjorkman	S.	Implications	of	coagulation	factor	
VIII	and	IX	pharmacokinetics	in	the	prophylactic	treatment	of	haemophilia.	Haemophilia	2011;	
17:	2–10.		
4		 Björkman	S,	Folkesson	A,	Jönsson	S.	Pharmacokinetics	and	dose	requirements	of	factor	VIII	over	
the	age	range	3–74	years.	Eur	J	Clin	Pharmacol	2009;	65:	989–98.		
5		 McEneny-King	A,	Iorio	A,	Foster	G,	Edginton	AN.	The	use	of	pharmacokinetics	in	dose	
individualization	of	factor	VIII	in	the	treatment	of	hemophilia	A.	Expert	Opin	Drug	Metab	Toxicol	
2016;	12:	1313–21.		
6		 Iorio	A,	McEneny-King	A,	Keepanasseril	A,	Foster	G,	Edginton	A.	What	is	the	role	for	population	
pharmacokinetics	in	hemophilia?	Int	J	Pharmacokinet	2017;	2:	125–36.		
7		 Björkman	S,	Collins	P.	Measurement	of	factor	VIII	pharmacokinetics	in	routine	clinical	practice.	J	
Thromb	Haemost	2013;	11:	180–2.		
8		 Brekkan	A,	Berntorp	E,	Jensen	K,	Nielsen	EI,	Jönsson	S.	Population	pharmacokinetics	of	plasma-
derived	factor	IX:	procedures	for	dose	individualization.	J	Thromb	Haemost	2016;	14:	724–32.		
9		 Nestorov	I,	Neelakantan	S,	Ludden	TM,	Li	S,	Jiang	H,	Rogge	M.	Population	pharmacokinetics	of	
recombinant	factor	VIII	Fc	fusion	protein.	Clin	Pharmacol	Drug	Dev	2015;	4:	163–74.		
10		 Karafoulidou	A,	Suarez	E,	Anastasopoulou	I,	Katsarou	O,	Kouramba	A,	Kotsi	P,	Zografidis	A,	Lukas	
JC.	Population	pharmacokinetics	of	recombinant	factor	VIII:C	(ReFacto??)	in	adult	HIV-negative	
and	HIV-positive	haemophilia	patients.	Eur	J	Clin	Pharmacol	2009;	65:	1121–30.		
11		 Bjorkman	S,	Oh	M,	Spotts	G,	Schroth	P,	Fritsch	S,	Ewenstein	BM,	Casey	K,	Fischer	K,	Blanchette	
VS,	Collins	PW.	Population	pharmacokinetics	of	recombinant	factor	VIII:	the	relationships	of	
pharmacokinetics	to	age	and	body	weight.	Blood	2012;	119:	612–8.		
12		 Diao	L,	Li	S,	Ludden	T,	Gobburu	J,	Nestorov	I,	Jiang	H.	Population	Pharmacokinetic	Modelling	of	
Recombinant	Factor	IX	Fc	Fusion	Protein	(rFIXFc)	in	Patients	with	Haemophilia	B.	Clin	
Pharmacokinet	2014;	53:	467–77.		
13		 Collins	PW,	Young	G,	Knobe	K,	Karim	FA,	Angchaisuksiri	P,	Banner	C,	Gürsel	T,	Mahlangu	J,	
Matsushita	T,	Mauser-Bunschoten	EP,	Oldenburg	J,	Walsh	CE,	Negrier	C.	Recombinant	long-
acting	glycoPEGylated	factor	IX	in	hemophilia	B:	A	multinational	randomized	phase	3	trial.	Blood	
2014;	124:	3880–6.		
14		 Santagostino	E,	Martinowitz	U,	Lissitchkov	T,	Pan-Petesch	B,	Hanabusa	H,	Oldenburg	J,	Boggio	L,	
Negrier	C,	Pabinger	I,	von	Depka	Prondzinski	M,	Altisent	C,	Castaman	G,	Yamamoto	K,	Alvarez-
Roman	M-T,	Voigt	C,	Blackman	N,	Jacobs	I.	Long-acting	recombinant	coagulation	factor	IX	
albumin	fusion	protein	(rIX-FP)	in	hemophilia	B:	results	of	a	phase	3	trial.	Blood	2016;	127:	1761–
9.		
15		 Sheiner	LB,	Beal	S,	Rosenberg	B,	Marathe	V	V.	Forecasting	individual	pharmacokinetics.	Clin	
Pharmacol	Ther	1979;	26:	294–305.		
16		 Iorio	A,	Keepanasseril	A,	Foster	G,	Navarro-Ruan	T,	McEneny-King	A,	Edginton	AN,	Thabane	L.	
Development	of	a	Web-Accessible	Population	Pharmacokinetic	Service—Hemophilia	(WAPPS-
Hemo):	Study	Protocol.	JMIR	Res	Protoc	JMIR	Research	Protocols;	2016;	5:	e239.		
17		 McEneny-King	A,	Foster	G,	Iorio	A,	Edginton	AN.	Data	Analysis	Protocol	for	the	Development	and	
Evaluation	of	Population	Pharmacokinetic	Models	for	Incorporation	Into	the	Web-Accessible	
Population	Pharmacokinetic	Service	-	Hemophilia	(WAPPS-Hemo).	JMIR	Res	Protoc	2016;	5:	e232.		
18		 Álvarez-Román	MT,	Fernandez-Bello	I,	de	la	Corte-Rodríguez	H,	Hernández-Moreno	AL,	Martín-
Salces	M,	Butta-Coll	N,	Rivas-Pollmar	MI,	Rivas-Muñoz	S,	Jiménez-Yuste	V.	Experience	of	tailoring	
prophylaxis	using	factor	VIII	pharmacokinetic	parameters	estimated	with	myPKFiT	®	in	patients	
with	severe	haemophilia	A	without	inhibitors.	Haemophilia	2017;	23:	e50–4.		
19		 Collins	PW,	Blanchette	VS,	Fischer	K,	Björkman	S,	Oh	M,	Fritsch	S,	Schroth	P,	Spotts	G,	Astermark	
J,	Ewenstein	B.	Break-through	bleeding	in	relation	to	predicted	factor	VIII	levels	in	patients	
receiving	prophylactic	treatment	for	severe	hemophilia	A.	J	Thromb	Haemost	2009;	7:	413–20.		
20		 Valentino	LA,	Pipe	SW,	Collins	PW,	Blanchette	VS,	Berntorp	E,	Fischer	K,	Ewenstein	BM,	Oh	M,	
Spotts	G.	Association	of	peak	factor	VIII	levels	and	area	under	the	curve	with	bleeding	in	patients	
with	haemophilia	A	on	every	third	day	pharmacokinetic-guided	prophylaxis.	Haemophilia	2016;	
22:	514–20.		
21		 Iorio	A,	Iserman	E,	Blanchette	V,	Dolan	G,	Escuriola	Ettingshausen	C,	Hermans	C,	Negrier	C,	
Oldenburg	J,	Reininger	A,	Rodriguez-Merchan	C,	Spannagl	M,	Valentino	LA,	Young	G,	Steinitz-
Trost	KN,	Gringeri	A.	Target	plasma	factor	levels	for	personalized	treatment	in	haemophilia:	a	
Delphi	consensus	statement.	Haemophilia	2017;	:	1–10.		
22		 Broderick	CR,	Herbert	RD,	Latimer	J,	Barnes	C,	Curtin	JA,	Mathieu	E,	Monagle	P,	Brown	SA.	
Association	Between	Physical	Activity	and	Risk	of	Bleeding	in	Children	With	Hemophilia.	JAMA	
2012;	308:	1452–9.		
23		 Hazendonk	H,	Fijnvandraat	K,	Lock	J,	Driessens	M,	van	der	Meer	F,	Meijer	K,	Kruip	M,	Gorkom	BL	
-v.,	Peters	M,	de	Wildt	S,	Leebeek	F,	Cnossen	M,	Mathot	R.	A	population	pharmacokinetic	model	
for	perioperative	dosing	of	factor	VIII	in	hemophilia	A	patients.	Haematologica	2016;	101:	1159–
69.		
24		 Hazendonk	HCAM,	Lock	J,	Mathôt	RAA,	Meijer	K,	Peters	M,	Laros-van	Gorkom	BAP,	van	der	Meer	
FJM,	Driessens	MHE,	Leebeek	FWG,	Fijnvandraat	K,	Cnossen	MH.	Perioperative	treatment	of	
hemophilia	A	patients:	Blood	group	O	patients	are	at	risk	of	bleeding	complications.	J	Thromb	
Haemost	2015;	14:	468–78.		
25		 Fischer	K,	Pendu	R,	van	Schooten	CJ,	van	Dijk	K,	Denis	C	V,	van	den	Berg	HM,	Lenting	PJ.	Models	
for	prediction	of	factor	VIII	half-life	in	severe	haemophiliacs:	distinct	approaches	for	blood	group	
O	and	non-O	patients.	PLoS	One	2009;	4:	e6745.		
26		 Peyvandi	F,	Oldenburg	J,	Friedman	KD.	A	critical	appraisal	of	one-stage	and	chromogenic	assays	
of	factor	VIII	activity.	J	Thromb	Haemost	2016;	14:	248–61.		
27		 Dodt	J,	Hubbard	AR,	Wicks	SJ,	Gray	E,	Neugebauer	B,	Charton	E,	Silvester	G.	Potency	
determination	of	factor	VIII	and	factor	IX	for	new	product	labelling	and	postinfusion	testing:	
challenges	for	caregivers	and	regulators.	Haemophilia	2015;	21:	543–9.		
28		 Iorio	A,	Fischer	K,	Blanchette	V,	Rangarajan	S,	Young	G,	Morfini	M.	Tailoring	treatment	of	
haemophilia	B:	accounting	for	the	distribution	and	clearance	of	standard	and	extended	half-life	
FIX	concentrates.	Thromb	Haemost	2017;	117:	1023–30.		
29		 Beal	SL.	Ways	to	Fit	a	PK	Model	with	Some	Data	Below	the	Quantification	Limit.	J	Pharmacokinet	
Pharmacodyn	2001;	28:	481–504.		
30		 Ahn	JE,	Karlsson	MO,	Dunne	A,	Ludden	TM.	Likelihood	based	approaches	to	handling	data	below	
the	quantification	limit	using	NONMEM	VI.	J	Pharmacokinet	Pharmacodyn	2008;	35:	401–21.		
	
	 	
Box	
Area	under	the	curve	(AUC):	area	beneath	the	activity	vs.	time	curve;	it	measures	the	“exposure”	to	the	
concentrate.	
Baseline	factor	level:	the	level	of	factor	activity	measured	in	plasma	in	absence	of	therapeutically	administered	
factor	concentrate.	It	is	the	level	of	factor	activity,	if	any,	endogenously	produced	by	the	individual.	Is	the	
factor	level	used	to	classify	the	patient	as	severe	(<0.01	IU/mL).	moderate	(0.01	to	0.05	IU/mL)	or	mild	
(>0.05	IU/mL).	
Below	limit	of	quantitation	(BLQ):	indicates	a	measurement	of	factor	level	activity	below	the	minimum	amount	
detected	by	the	laboratory	assay.	Most	often	BLQ	values	are	reported	as	“undetectable”,	or	“not	
measurable”,	or	<0.01	IU/mL.	
Clearance:	volume	of	blood	from	which	the	factor	activity	is	removed	in	a	specified	unit	of	time.	
Half-life:	The	time	required	for	the	plasma	activity	level	to	decrease	by	half.	It	is	qualified	as	terminal	half-life	
when	estimated	on	the	last	portion	of	the	activity	over	time	profile,	when	the	elimination	of	the	activity	
become	constant.	
Recovery:	amount	of	factor	level	activity	measured	in	the	plasma	as	proportion	of	the	amount	of	concentrate	
infused.	
Lean	Body	Weight:	residual	body	weight	after	subtraction	of	the	fat	component	(equal	or	more	often	inferior	to	
the	body	weight)	
Mean	residence	time	(MRT):	the	average	amount	of	time	that	a	single	molecule	unit	of	activity	stays	in	the	body	
or	plasma	
Volume	of	distribution:	the	theoretical	volume	that	would	be	necessary	to	contain	the	total	amount	of	a	factor	
concentrate	to	generate	the	same	activity	level	that	it	is	observed	in	the	plasma.	
Wash-out:	Time	spent	off-treatment	before	a	conventional	PK	study	to	ensure	no	residual	factor	activity	level	
generated	by	the	factor	concentrate	is	present	in	the	blood.	Usually	equal	or	longer	than	5	times	the	
anticipated	half-life.	The	residual	measurable	activity	level	after	an	appropriate	wash-out	is	the	baseline	
factor	level.	
